

REGENERON PHARMACEUTICALS INC

Form 8-K

April 01, 2003

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

---

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report: March 28, 2003  
(Date of earliest event reported)

**REGENERON PHARMACEUTICALS, INC.**

(Exact name of Registrant as specified in its charter)

New York  
(State or Other Jurisdiction of  
Incorporation)

0-19034  
(Commission File Number)

13-3444607  
(IRS Employer  
Identification No.)

**777 Old Saw Mill River Road  
Tarrytown, NY 10591-6707**  
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (914) 347-7000

---

**ITEM 5. OTHER EVENTS**

On March 28, 2003, the Company issued a press release announcing its Collaboration, License and Option Agreement with Novartis Pharma AG, a copy of which is attached to this filing.

On March 31, 2003, the Company issued a press release announcing the results of its Phase III obesity study. This release as issued contained a statement that AXOKINE treatment achieved statistically significant results in all secondary endpoints of the study. A corrected press release is attached to this filing, which clarifies that AXOKINE treatment achieved statistically significant results in two of the three secondary endpoints.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS**

(c) Exhibits.

99a Press Release dated March 28, 2003

99b Press Release dated March 31, 2003 (As Corrected)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

By: /s/ Stuart Kolinski

Name: Stuart Kolinski  
Title: Vice President & General Counsel

Date: April 1, 2003